SCHEDULE 13D/A: Kronos Bio Acquired by Concentra Biosciences, Major Shareholder Divests All Holdings

Kronos Bio, Inc. has been acquired by Concentra Biosciences, LLC, leading to the complete divestment of common stock by Norbert Bischofberger, Ph.D. and related trusts.

Summary

• Kronos Bio, Inc. completed its merger with Concentra Biosciences, LLC on June 20, 2025, becoming a wholly-owned subsidiary of Concentra.
• As a result of the merger, each outstanding share of Kronos Bio's Common Stock was converted into the right to receive $0.57 in cash and one contractual contingent value right (CVR).
• Outstanding stock options were immediately vested, exercisable, cancelled, and converted into the equivalent merger consideration.
• Norbert Bischofberger, Ph.D. and associated trusts (the "Reporting Persons") sold all their common stock in Kronos Bio, Inc. as part of this merger.
• The Reporting Persons ceased to be beneficial owners of at least five percent of Kronos Bio's Common Stock as of June 20, 2025.
• Norbert Bischofberger, Ph.D. also ceased to be a director of Kronos Bio, Inc. at the effective time of the merger.

Sentiment

Score: 5

Explanation: The document is purely factual, reporting a completed corporate transaction and the resulting change in beneficial ownership. It does not contain subjective language or forward-looking statements that would indicate a positive or negative sentiment beyond the objective reporting of the merger terms.

Positives

• The merger provides immediate liquidity to shareholders through a cash payment of $0.57 per share.
• Shareholders also receive contingent value rights (CVRs), offering potential future cash payments based on specific milestones or outcomes.
• The acquisition by Concentra Biosciences, LLC could provide Kronos Bio with new strategic direction and resources as a wholly-owned subsidiary.

Negatives

• Kronos Bio, Inc. has ceased to be an independent publicly traded company, becoming a wholly-owned subsidiary.
• The Reporting Persons, including Norbert Bischofberger, Ph.D., have fully divested their ownership, meaning they will no longer participate in the company's future equity upside beyond the CVRs.

Risks

• The value of the contingent value rights (CVRs) is uncertain and depends on future events, which may or may not occur, potentially limiting the total return for former shareholders.

Future Outlook

Kronos Bio, Inc. is now a wholly-owned subsidiary of Concentra Biosciences, LLC, and its future operations and strategic direction will be determined by Concentra. Former shareholders will receive contingent cash payments based on the terms of the CVR Agreement.

Industry Context

This filing reflects a consolidation event within the biotechnology or pharmaceutical sector, where a smaller public company (Kronos Bio) is acquired by another entity (Concentra Biosciences). Such mergers are common in the industry, driven by factors like pipeline assets, market positioning, or strategic realignment.

Management Changes

Legal Proceedings

• The Reporting Persons have not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
• The Reporting Persons have not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws during the last five years.

Stakeholder Impact

• Shareholders: Received $0.57 cash per share and one CVR for each share, converting their equity into cash and a contingent right.
• Management/Directors: Norbert Bischofberger, Ph.D. ceased his directorship, indicating a change in the company's leadership structure post-acquisition.

Next Steps

• Former shareholders holding CVRs will await potential contingent cash payments based on the terms outlined in the CVR Agreement.

Key Dates

Keywords

Kronos Bio, Concentra Biosciences, Merger, Acquisition, Schedule 13D, Beneficial Ownership, Share Sale, Contingent Value Right, CVR, Biotechnology, Pharmaceutical